On this page
At this year’s in-cosmetics Global, the R&D tours did more than spotlight emerging ingredients - they revealed a deeper shift in how the industry is thinking about skin itself. Across the three core themes - biotech innovation, skin sensitivity, and longevity - a unifying narrative emerged: cosmetic science is moving away from surface-level solutions and toward biologically intelligent, system-based approaches to skin health.
Each tour, sponsored by Mibelle Biochemistry, Natura-Tec, and Symrise respectively, offered a distinct perspective. Yet taken together, they highlighted an industry increasingly defined not by individual ingredients, but by how those ingredients interact with the skin’s underlying biology.
Sponsored by Mibelle Biochemistry - Biotechnology is no longer a frontier - it is fast becoming the foundation of modern ingredient development. What stood out across the Biotech Innovations: Exosomes and Beyond tour was not just the diversity of technologies on display, but the consistency of direction: precision, scalability, and biological alignment.
Mibelle Biochemistry’s featured ingredient, EpiSnow™, exemplifies this shift. Derived from extremophile snow algae, the ingredient leverages the organism’s natural ability to survive in high-stress alpine environments. These survival mechanisms translate into bioactive compounds that support skin resilience and cellular protection.
Crucially, EpiSnow™ is not positioned as a single-function active. Instead, it targets multiple biological pathways associated with ageing, including cellular senescence, collagen synthesis, and metabolic activity. This reflects a broader evolution in formulation thinking - from isolated claims to multi-pathway, systems-level efficacy.
At the same time, biotech is solving a parallel challenge - sustainability. Lab-based production reduces reliance on natural resource extraction, while innovations such as fermentation-derived lipids and algae-based actives offer scalable alternatives to traditional raw materials.
Sponsored by Natura-Tec - If biotech represents a technological shift, then the evolution of skin sensitivity represents a conceptual one. The Innovation in Skin Sensitivity tour reinforced that sensitivity is no longer a niche skin type, but a dynamic condition driven by barrier dysfunction, inflammation, and environmental stress.
Natura-Tec’s portfolio reflects this shift through barrier-supportive, lipid-rich ingredients designed to restore the skin’s protective function rather than simply soothe symptoms.
At the same time, the category is becoming more sophisticated. The rise of microbiome-conscious formulation and neurocosmetics highlights a broader move toward understanding not just how skin looks, but how it behaves and responds.
What becomes clear here is that sensitivity is often the visible manifestation of deeper biological imbalance - a point that directly connects it to both biotech and longevity.
Sponsored by Symrise - if one theme captured the industry’s shift in mindset, it was longevity. The Longevity tour, sponsored by Symrise, reinforced the idea that traditional anti-ageing is being replaced by a more holistic objective: maintaining skin function over time.
Symrise’s Cellexora™ MD, based on plant-derived extracellular vesicles, reflects this shift toward cellular communication and regeneration.
Positioned within the concept of “healthspan”, the ingredient focuses not just on extending the lifespan of skin cells, but preserving their optimal performance - targeting processes such as cellular senescence, oxidative stress, and inflammation.
What became increasingly evident throughout the tours is that these three themes are not operating in isolation - they are different entry points into the same biological narrative.
In this context, sensitivity can be seen as an early signal of compromised longevity, often driven by inflammation and environmental stress. Biotech, in turn, offers the means to intervene more effectively - whether through enhanced delivery systems, cellular signalling, or sustainable sourcing of complex actives.
This convergence points toward a fundamental shift: the industry is moving from treating symptoms in isolation to addressing interconnected biological systems.
Rather than asking “What does this ingredient do?”, the more relevant question is becoming:
“How does this ingredient influence the overall function of the skin?”
What these tours ultimately revealed is a shift in perspective. The industry is no longer just developing ingredients or products - it is building biologically coherent systems.
Biotech enables precision.
Sensitivity reveals imbalance.
Longevity sets the long-term goal.
Together, they signal a move toward a more integrated, intelligent approach to formulation - one that prioritises function over claims, prevention over correction, and systems over single solutions.
For an industry historically driven by trends, this may be the clearest indication yet that the future of beauty lies not in what is new, but in what is fundamentally understood.
The views expressed in this article are those of the author and do not necessarily reflect the views of Covalo.